📝 Results from a phase II trial published in Blood Advances found that tocilizumab was associated with reduced Grade 1–4 lower GI #aGvHD incidence (p = 0.056) compared with no tocilizumab in patients with hematologic malignancies. More news: gvhdhub.com #GvHD

During the GvHD Hub Steering Committee Meeting, @NicoGagelman shared findings from a German retrospective study investigating the efficacy of ECP + ruxolitinib vs ruxolitinib alone in patients with SR-aGvHD. Watch the full discussion here: loom.ly/4tkgPLA #GvHD

New publication 📝 A 2025 update from the NIH Consensus Conference, published in Transplantation and Cellular Therapy Journal, highlights major progress in cGvHD prevention with PTCy in the RIC setting. Learn more: loom.ly/QaTET08 #GvHD #cGvHD #MedNews #MedEd

New publication 📝 Real-world results of MaaT013, presented by Mohamad Mohty at #EHA2025, show 53% Day 28 GI-ORR in patients with SR/SD GI-aGvHD; most responders achieved VGPR. Learn more: loom.ly/wfMJOxw #GVHD #MedEd #MedNews

📝 A 2025 update from the NIH Consensus Conference, published in Transplantation and Cellular Therapy Journal, recommends that implementation of community-based efforts for early identification and diagnosis of cGvHD are essential. More news: GvHDhub.com #GvHD #cGvHD #MedNews #MedEd

📝 A new study presented at #EHA2025 by Mohamad Mohty highlights MaaT013 as a potential microbiota-based option for SR/SD GI-aGvHD, with consistent efficacy and survival across real-world and trial settings. More news: gvhdhub.com #GvHD #MedNews #MedEd

Listen to our expert steering committee discuss how to improve measurement of QoL and use of PROs in chronic GvHD: loom.ly/zfJtjUU #GvHD #MedNews #MedEd

During the GvHD Hub Steering Committee Meeting, Mohamad Mohty discussed the use of Lee Symptom Scale PRO tool in the management of cGvHD. Watch the full discussion on measurement of QoL and use of PROs tools in cGvHD here: loom.ly/sCszLFg #GvHD #MedNews #MedEd

Did you know you can filter content on the #GvHD Hub website depending on your specific interests – whether that is by GvHD type, therapeutics, trials, or congresses? 👉 loom.ly/h0tWtwA #MedEd #gvhds

New publication 📝 A post-hoc analysis published in the International Journal of Hematology shows higher rates of lower-GI aGvHD-FS with vedolizumab vs placebo prophylaxis in Japanese patients post allo-HSCT (94% vs 81%). Learn more: loom.ly/rYYBIVc #GvHD #aGvHD

📝 A post-hoc analysis from the GRAPHITE trial published in the International Journal of Hematology shows higher rates of lower-GI aGvHD-FS with vedolizumab vs placebo prophylaxis in non-Japanese patients post allo-HSCT (84% vs 70%). More news: GvHDhub.com #GvHD

New data 📝 Phase III results of the ALLG BM12 CAST trial, presented by David Curtis at #EHA2025, show the 3-year GvHD-free, relapse-free survival was higher in the PTCy + CsA group vs CsA + MTX (49% vs 14%; HR, 0.42; p < 0.001). 👉 loom.ly/JWtqQO0 #GvHD #aGvHD #cGvHD

During the GvHD Hub Steering Committee Meeting, @NicoGagelman shared findings from a German retrospective study investigating the efficacy of ECP + ruxolitinib vs ruxolitinib alone in patients with SR-aGvHD. Watch the full discussion here: loom.ly/4tkgPLA

📝 Phase III results of the ALLG BM12 CAST trial, presented by David Curtis at #EHA2025, found that the 2-year relapse-free survival was prolonged in the PTCy + CsA group vs CsA + MTX (74% vs 59%; HR, 0.55; p = 0.045). More news: GvHDhub.com #GvHD #aGvHD #cGvHD

⭐GvHD hub spotlight: Key findings from a German retrospective study investigating ruxolitinib + ECP in SR-aGvHD⭐ A publication by Lastovytska et al. in Haematologica reported long-term outcomes with ruxolitinib + ECP vs ruxolitinib alone in SR-aGvHD. #GvHD #GvHDsm #MedEd

HCPs, please let us know your thoughts! When would you be most likely to consider prescribing belumosudil third-line and beyond?

New publication 📝 3-year final analysis of the REACH3 trial, published in Journal of Clinical Oncology, shows ruxolitinib achieved longer median FFS (38.4 months vs 5.7 months) and DoR (not reached vs 6.4 months) vs best available therapy in patients with SR/D-cGvHD. Learn more:

Data from a German retrospective study investigating ruxolitinib + ECP vs ruxolitinib alone in patients with SR-aGvHD demonstrated a significant cGvHD relapse-free survival benefit with ECP combination therapy. Learn more: loom.ly/NbnWPy4 #GvHD #GvHDsm #MedEd

📝 3-year final analysis of the REACH3 trial, published in Journal of Clinical Oncology, found that ruxolitinib-treated patients with SR/D-cGvHD had a higher probability of FFS (56.5% vs 18.2%) and maintaining a response (59.6% vs 26.7%) at 36 months vs those receiving best available therapy.